Mark Eckert, PhDUniversity of Chicago Targeting T-LAK cell-originated protein kinase (TOPK) for ovarian cancer therapy Ovarian cancer is one of the most lethal cancers due to a lack of effective therapies. Dr. Eckert’s lab recently found that the protein T-LAK cell-originated protein kinase (TOPK) is expressed in ovarian cancer cells, but not most normal tissues. […]
Read More
Remi Buisson, PhDMassachusetts General Hospital Unraveling the role of ATR in DNA repair and ovarian cancer therapy Proteins involved in the surveillance of genomic integrity, including BRCA1, BRCA2, and PALB2, help detect damage to DNA in cells and ensure that repairs are made when needed. Cells with mutations in BRCA1, BRCA2, and PALB2 have been […]
Read More
David Pepin, PhDMassachusetts General Hospital AAV9 gene therapy using a novel engineered MIS to treat ovarian cancer Ovarian cancer tumors are made up mostly of cells that respond well to chemotherapy, but a minority of stem-like cells survive treatment and ultimately lead to chemoresistant recurrence. However, this type of cancer stem cell is inhibited by […]
Read More
Erin George, MDUniversity of Pennsylvania2016 Skacel Family Scholar Targeting the ATR/CHK1 pathway in high grade serous ovarian cancer with ATR inhibitors New treatments are needed for recurrent ovarian cancer, a subset of which is more aggressive than the original cancer and has no effective treatment. Aggressive recurrent cancers rely on DNA repair pathways, involving proteins […]
Read More
Yasuto Kinose, M.D., Ph.D.University of PennsylvaniaPhiladelphia, PA, United States2018 SKACEL FAMILY SCHOLAR Project: Evaluation of a novel combination therapy in clear cell ovarian cancer orthotopic patient-derived xenograft models Research Area: Novel Therapy, Cancer Biology Summary:While clear cell ovarian cancer is a relatively rare subtype of ovarian cancer, it is also the most difficult to treat in advanced […]
Read More
Kwan Ho Tang, PhDNew York UniversityNew York, NY, United States 2019 Scientific Scholar Award Research in Focus: Novel therapies to treat ovarian cancer Targeting SHP2 and MEK in High-Grade Serous Ovarian Cancer High-grade serous ovarian cancer is the most lethal gynecological disease. Dr. Tang and colleagues have shown in that a combination treatment of SHP2 inhibitor […]
Read More
Achuth Padmanabhan, PhDBaylor College of Medicine2019 Skacel Family Scholar PROTAC-mediated degradation of oncogenic gain-of-function p53 mutants: A personalized therapeutic strategy for ovarian cancer Ovarian cancer is the fifth leading cause for cancer-associated deaths among women in the US and is associated with frequent mutations in p53 gene. While some mutations result in the loss of […]
Read More
Erin George, MDUniversity of Pennsylvania2019 Lynda’s Fund Scholar Award Strategies to optimize drug tolerability without compromising efficacy Most women with ovarian cancer present with advanced stage disease. Large surgeries and toxic chemotherapies are the mainstay of treatment and, despite advances in medicine, most ovarian cancers return. Every tumor is unique in its biology, allowing for […]
Read More
Sarah Beth Gitto, PhDUniversity of Pennsylvania2019 Scientific Scholar Award Priming the TME with anti-VEGF to enhance the efficacy of dual checkpoint inhibition in PARPi-resistant OC Recent studies have shown that the use of the PARP inhibitor olaparib increases survival of ovarian cancer. Unfortunately, most patients will become resistant to PARP inhibitors, thus novel treatment strategies […]
Read More
Yang Yang-Hartwich, PhDYale University2015 Cookie Laughlin Bridge Funding Award Targeting p53-regulated Twist1 Degradation to Inhibit Ovarian Cancer Metastasis Metastasis is a hallmark of advanced high-grade serous ovarian carcinoma. Turning off the ability of ovarian cancer to spread or metastasize to other places in the body would provide better therapies and prevent recurrence. The objective of […]
Read More